#teva-v-amneal

#teva-v-amneal

The Federal Circuit's decision in Teva v. Amneal could redefine pharmaceutical patent listing requirements under the Hatch-Waxman Act.

The ruling may impact how device patents related to drugs are treated in the FDA's Orange Book.

The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.

The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.

The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.